Libraries of highly annotated small molecules have many uses in chemical genetics, drug discovery and drug repurposing. Many such libraries have become available, but few data-driven approaches exist to compare these libraries and design new ones. In this paper, we describe such an approach that makes use of data on binding selectivity, target coverage and induced cellular phenotypes as well as chemical structure and stage of clinical development. We implement the approach as R software and a Web-accessible tool (http://www.smallmoleculesuite.org) that uses incomplete and often confounded public data in combination with user preferences to score and create libraries. Analysis of six kinase inhibitor libraries using our approach reveals dramatic differences among them, leading us to design a new LSP-OptimalKinase library that outperforms all previous collections in terms of target coverage and compact size. We also assemble a mechanism of action library that optimally covers 1852 targets of the liganded genome. Using our tools, individual research groups and companies can quickly analyze private compound collections and public libraries can be progressively improved using the latest data.
INTRODUCTION
The size and diversity of small molecule libraries is an important design criterion: the larger the number of compounds, the greater the probability of finding a high affinity hit and the more protein targets that can be included; the smaller the library, the greater the feasibility of studying doseresponse relationships, drug combinations and sensitizing conditions [1] [2] [3] [4] [5] [6] . Focused small molecule libraries (typically comprising ~ 30-3,000 compounds) are widely used to identify potential therapeutic targets, study biological processes and uncover drug repurposing opportunities 7 . Focused libraries are particularly advantageous (relative to large compound collections) with phenotypic assays, as illustrated by the identification in such collections of "first-in-class" drugs [8] [9] [10] such as Vorinostat 11 and
Miglustat 12 and the repurposing of drugs such as LY500307 (Erteberel) for schizophrenia. 13 Despite this, few data-driven approaches exist to evaluate existing compound collections or design new ones.
Many focused libraries concentrate on a single druggable multigene family, such as kinases or ion-channels, FDA-approved drugs or the liganded genome 14 (the subset of proteins bound by at least three compounds at Ki < 10 µM); libraries against the liganded genome are commonly referred to as "Mechanism of Action" (MoA) libraries because they can be helpful in dissecting biological mechanism 15 . Such libraries have become available through public initiatives 16 , outreach by pharmaceutical companies 17 , commercial small molecule vendors and expert-curated lists of "optimal" compounds [18] [19] [20] , (e.g. www.chemicalprobes.org). In principle, choosing a library should be relatively simple: optimal libraries include as many bioactive and highly selective compounds as necessary to cover a target class of interest, with the possible addition of approved and investigational therapeutics.
Achieving this in practice is difficult, since many compounds exhibit polypharmacology (that is, they bind to multiple protein targets) and data on polypharmacology are frequently incomplete. It can therefore be difficult to determine whether a drug-induced phenotype of interest is due to inhibition of the nominal target, a secondary target or both 18 .
In this paper, we describe a set of algorithms and software tools for optimizing the composition of focused small molecule libraries based on binding selectivity, structural diversity, similarity in cellbased assay activities and stage of clinical development. Our approach aims to minimize the number of compounds in a library while preserving diversity and other desirable characteristics. We compare six kinase-focused libraries and find that they vary substantially in chemical diversity and the range of targets covered. We therefore assemble a new LSP-OptimalKinase library with properties superior to any existing compound collection in terms of target coverage and compound selectivity. We also generate a compound list for an LSP-MoA library that optimally targets the liganded genome. Since libraries are created using software, they can easily be updated as new information on small molecules and their targets becomes available.
RESULTS
In this study, we use four types of information curated in ChEMBL and other data sources to analyze small molecule libraries: (i) chemical structure, (ii) "target data" (iii) "nominal target" and (iv)
"phenotypic data" (from drug-treated cells). Target "dose-response data" are most commonly derived from enzymatic assays with recombinant or purified proteins at >5 drug concentrations, yielding curves from which Ki or IC50 values can be derived. Target "profiling data" primarily involves assays with large panels of recombinant proteins, or proteins present in cell-free extracts, and yields information on binding to many different targets, which is often expressed as percent activity against each target (see for example DiscoverX KINOMEscan (https://www.discoverx.com/home) and Kinativ (http://www.kinativ.com/) [21] [22] [23] "Nominal target" is the target a small molecule was designed to agonize or inhibit, or that it is generally assumed to target, but it may not be the highest affinity or most biologically significant. "Phenotypic data" comprise experimental data from cell-based assays in which drug activity is measured using a morphological, biochemical, genetic or functional readout but drug-target engagement is not determined directly (e.g. drug-induced changes in proliferation, apoptosis, migration, immune-cell activation, transcription factor translocation, etc.).
The data sources used in this work comprised the ChEMBLV22_1 database 24 , which draws on data published in the scientific literature, patents, PubChem bioassays, FDA approval packages and other resources 25 ; kinome-wide screens from the International Centre for Kinase Profiling (http://www.kinase-screen.mrc.ac.uk); kinome-wide screens from LINCS 16 ; and in-house curation of nominal targets ( Figure S1 ). To correctly combine data for a single compound under different names (e.g. OSI-774, Erlotinib and Tarceva®) we matched chemical structures using the Tanimoto similarity of Morgan2 fingerprints (hereafter "structural similarity") 26 .
Our analysis of focused libraries involves six widely available inhibitor libraries with public annotations (Table S1) ; Tables S2 and   S3C ).
Chemical similarity within libraries
With respect to composition, we found that the LINCS and SK libraries shared ~50% of their compounds, making them the most similar among the six libraries examined ( Figure 1A ). In contrast, 350 of 362 compounds in the PKIS library were unique. To visualize structural diversity, we plotted chemical similarity against itself; the presence of highly similar compounds (analogues) gives rise to off-diagonal clusters. The LINCS library generated few such clusters whereas the PKIS library was dominated by them ( Figure 1B ). By way of illustration, a 3-compound cluster of LINCS analogues comprised the CDK inhibitor Seliciclib, and two close relatives, Olomoucine II and (S)-CR8 ( Figure 1B bottom). Seliciclib progressed to phase II for nasopharyngeal carcinoma, but failed to meet its primary endpoint of improving progression free survival 27, 28 , while the other compounds are reported to have improved cellular potency and selectivity 29, 30 . A 9-compound PKIS cluster contained a set of close analogs, none of which have progressed into clinical development ( Figure 1B, bottom) . By scoring the frequency and sizes of clusters having structural similarity ≥0.7 we find that the LINCS and Dundee collections are the most structurally diverse, PKIS the least, and SK, SP and EMD in-between ( Figure   1C ). This arises because LINCS, Dundee and SK compounds were drawn from different drug discovery campaigns across multiple companies and research groups, whereas the PKIS library was derived from structure-activity studies inside a single company.
Phenotypic similarity and clinical development
To assess the diversity of phenotypes elicited by different compounds, we constructed phenotypic fingerprint (PFP) vectors that quantify activity in a wide range of phenotypic assays curated in ChEMBL. 34, 35 . For compounds in the LINCS library we compared correlation coefficients for pairs of PFP vectors with correlation in CMAP L1000 profiles (using level 5 characteristic direction vectors 36 ). The great majority (73%) of compounds exhibited phenotypic correlation (set at a threshold of r ≥ 0.2 L1000, r ≥ 0.25 PFP) or non-correlation (|r| < 0.2 L1000, r < 0.25 PFP) by both metrics but a subset (27%) where discordant ( Figure 2C ). For example, when pairs of compounds targeting PI3K-MTOR-AKT signaling were compared, L1000 profiles were more likely to be correlated than PFP values, which is consistent with data showing that phenotypic responses to such drugs can be highly cell-type specific 36 . A similar phenomenon was observed for compounds targeting the RAF-MEK-ERK network.
The stage of clinical development is the final additional criterion on which to evaluate compounds in a library since the study of approved or investigational therapeutics has intrinsic value, even when such compounds do not substantially contribute to library diversity. LINCS has the greatest number of approved drugs (n=67; 14% of total); SK has the greatest number of compounds that are currently or have previously been tested in phased clinical trials (n=137; 32%); SP has the highest proportion of approved drugs (n=54; 57%) and PKIS the lowest (0%) ( Figure 2D ). Below we describe how clinical stage and compound diversity can be balanced against each other during library assembly.
Compound selectivity and library coverage
Compounds are commonly described with respect to their nominal target (e.g. a "BRAFinhibitor", in the case of Dabrafenib). However, this does not mean that the nominal target is the highest affinity target or the most biologically or clinically relevant. Crizotinib, for example, was developed as an inhibitor of the cMET receptor, but was subsequently found to inhibit ROS1 and ALK kinases. In culture it was observed that apoptosis was induced specifically in NSCLC lines carrying an EML4-ALK translocation 37 and the FDA initially approved the drug for this indication 38 . In general, it is difficult to determine which target is most relevant for a specific phenotype, nor is it always clear that any single target -rather than a collection of targets -is responsible for biological activity. We therefore used the selectivity score developed by Wang et al 7 , which assesses selectivity for each compound-target interaction, rather than for a compound overall, while accounting for data bias.
Selectivity score evaluates compound-target pairs based on the log-distribution of on-target affinities relative to the log-distribution of off-target affinities; this yields a selectivity score for every target against which a compound has been tested. Selectivity score measures the magnitude of difference in the first quartile of the on-target and off-target distributions (q1) and determines the rank sum p-value to assess significance. The selectivity score accounts for the fact that many compounds have only been evaluated on a relatively small number of targets, which can falsely give the impression that a compound is known to be highly selective. For example, selectivity is judged to be higher for compound A than compound B if A has been tested against a large number of targets and found to not bind most of them even if B has a higher affinity for a particular target of interest but has not be tested against alternative targets. It should be noted that like other features used to assess compounds in this study, selectivity score changes over time as additional data become available.
Selectivity score is a continuous variable but for convenience we also assigned descriptive labels to different classes of compound-target interaction. Most Selective (MS) interactions meet four criteria: (i) the difference in q1 values computed for the distributions of on-and off-target data is not less than 100-fold, (ii) the distributions of on-target and off-target binding affinities differ with p-value below 0.1 (iii) the compound has at least four-fold more off-target than on-target affinity measurement (so that data bias is below 20%), (iv) at least two published reports establish that the affinity for drug-target interaction is less than 100 nM. Semi-Selective (SS) interactions have slightly less stringent criteria: (i) the difference in q1 values is not less than 10-fold, (ii) the p-value for on and offtarget binding affinities is below 0.1 (iii) at least four publication report affinity under 1 µM (because the affinity cut-off is less stringent than for interactions meeting MS criteria, more data-points are needed to establish confidence in binding). Poly-Selective (PS) interactions are those for which: (i) q1
values for on-and off-target binding are similar, (ii) on-target q1 is under 9 µM (iii) data bias is under 20%. Unknown (UN) interactions are those for which the compound has not been sufficiently probed for off-target binding but fulfills the PS requirements with respect potency and affinity for the nominal target.
The requirement for such a multi-parametric approach is exemplified by the tool compound PP121, whose nominal targets are BCR/ABL1 and PDGFR, and Dasatinib, an approved drug whose nominal targets are BCR/ABL1, Src family kinases and PDGFR. Dasatinib has more known targets with an affinity between 1nM and 1 µM than PP121 ( Figure 3A ; red circles), but it has also been tested on a substantially larger number of kinases. In many cases, it exhibits no inhibitory activity against these offtargets (Ki > 10 µM, black). Thus, the selectivity score for Dasatinib (score = 1.1) is substantially higher than that of PP121 (0.44). We found that the LINCS and SK libraries had the largest number of kinases with MS interactions and the PKIS library the fewest ( Figure 3B ).
Evaluating compound similarity on binding spectrum
To compare compounds based on all known targets and known non-targets, we sought a means to summarize all available data on a compound, including dose-response data, profiling data and curated annotations from the literature (e.g. "drug X was found to not inhibit ..." or "was equipotent
for ..."). The resulting Target Affinity Spectrum (TAS) vectors summarize binding information from
multiple assay formats weighted for the degree of evidence for high affinity binding and also for nonbinding (Kd > 10 µM). TAS vectors contain some best-guess weighting parameters and are therefore less precise than selectivity scores, but they provide a more complete picture of available data ( Figure   4A ).
For the LINCS library, TAS vectors varied in length from a median of 10 features for probe compounds (range 1-394) and 15 for approved drugs (range 1-420), (Wilcoxon rank-sum test p=0.07).
In no cases did a TAS include assertions for all 545 human kinases 39 , let alone for all ~3000 members of the ligandable genome 40 , illustrating the sparseness of target annotation. TAS similarities for all compound pairs were calculated using a weighted Jaccard similarity metric (see methods). We found that TAS similarity was robust to at least 20% random variation in user-assigned weights ( Figure S3 ).
We compared TAS vectors computed from ChEMBLV22_1 and other resources to data from a systematic assessment of kinase-inhibitor binding recently published by Klaeger et al 41 that uses whole-cell lysates and mass spectrometry to profile compound-target binding (ChEMBL does not yet include this data). Surprisingly, the target coverage of the two datasets only partially overlapped, with a typical LINCS compound having one-third of its targets annotated in both datasets and one third in only one of the two datasets ( Figure S5A ). The reasons for differences in target spectrum as curated by ChEMBL and measured by Klaeger et al. are not yet clear and may relate to the range of targets evaluated in each case, but for targets annotated in both sources, 90% of the target-affinity assertions were congruent ( Figure S5B ).
We also asked whether knowledge of a molecules' nominal target was informative about target spectrum by comparing TAS similarities for compounds with the same or different nominal targets.
Remarkably, we found that the distribution of TAS similarities was very similar for compounds having 
Relationship among structural, phenotypic and target similarity
For many compounds, data on target spectrum and induced cellular phenotype are sparse and selectivity score or TAS vectors might not be computable. We asked whether, in these cases, structural similarity could be used as a surrogate. In general, we found that structural similarity is a relatively poor predictor of phenotypic similarity: for example, the likelihood that compounds with structural similarity 0.7 (representing the Tanimoto similarity of Morgan2 fingerprints) or higher will induce similar phenotypes (i.e. exhibit a PFP correlation ≥ 0.9) is only 10% ( Figure 5B ). We also found that for compounds in the LINCS library (which has high structural diversity), structural similarity and target similarity were not correlated ( Figure 5C ). This was confirmed in the case of a subset in the PKIS library that shared the same core structure: structural similarity did not predict target similarity ( Figure 5D ).
However, the converse appear to be true: when compounds had low structural similarity (≤ 0.2; Figure   5A ) they were more likely to induce different phenotypes and have different target spectra. Thus, structural, phenotypic and target similarity contain non-redundant information about small molecule similarity. However, when data on target selectivity is missing, it is possible to exploit the finding that structures with very low similarity (≤ 0.2) have the highest likelihood of being diverse at the phenotypic and target levels.
Designing an improved kinase inhibitor and a mechanism of action library
To enable construction of new libraries using the methods described above, we created the LibraryR software tool and deployed it as a web application using R-Shiny (http://www.smallmoleculesuite.org). For a user-specified set of genes LibraryR mines ChEMBL to create libraries containing (i) two compounds maximally specific for each gene of interest but having structural similarity ≤ 0.2, so that overlap in secondary targets is minimized (ii) all available compounds at a user-specified clinical stage (e.g. clinical phases 1-3 or approved) that also bind to the genes of interest with user-specified affinity (default Ki ≤ 1µM). LibraryR also calculates the selectivity score for each compound and assigns each compound to selectivity classes (MS, SS, PS, UN; Figure 6A ). We used
LibraryR to construct an improved version of the LINCS kinase library (the Laboratory of Systems
Pharmacology LSP-OptimalKinase library; Table S14 ) and a mechanism of action library that optimally targets the liganded genome (LSP-MoA; Table S15 ). Tier B compounds extends MS and SS coverage to 37 additional kinases ( Figure 6E , Figure 3C ) while including many more compounds in clinical development ( Figure 6F ). However, the further addition of 343 Tier C and D compounds extends coverage to only 10 additional kinases at PS and UN selectivity.
Thus, computation-driven library design can reduce the size (and cost) of screening libraries and the studies that use them, while increasing target coverage and maintaining library diversity.
The LSP-MoA library is designed to target the 1852 members of the liganded genome (Table S9) about 12% of which can be bound with MS selectivity, 10% maximally with SS selectivity, 44% maximally with PS or UN selectivity; 34% of kinases are bound only by compounds that are known to have a higher affinity for another target ( Figure 6C ). In the case of targets bound with UN selectivity, 61
involved relatively tight binders (compounds with Kd < 100 nM) for which little selectivity data is available. Such compound-target pairs would benefit disproportionately from more data on possible off-targets (e.g. obtained by profiling). We analyzed LSP-MoA for its coverage of five therapeutic target classes: kinases, G-protein-coupled receptors (GPCRs), ion channels (ICs), nuclear hormone receptors (NHRs), and transporters (supplementary Tables 7, 10-13) . Kinases were by far the best covered with 136 of 545 kinases (25%) at MS selectivity, followed by 28 of 416 GPCRs (7%), 2 of 49 NHRs (4%), 2 of 285 ICs (0.7%) and 1 of 510 transporters (0.1%; Figure 6D ). The same trend was also observed for the understudied ('dark') ligandable genome as recently curated by the NIH (https://commonfund.nih.gov/idg Tables S7, S10, S11).
DISCUSSION
The ideal focused library of annotated, biologically active small molecules comprises the minimal number of compounds necessary to cover a gene set of interest selectively while optionally including additional approved and investigational drugs. Achieving optimal coverage is difficult in practice since many small molecules bind multiple targets and data on target spectra are nearly always incomplete and subject to poorly understood experimental confounders. Moreover, in many cell-based screening projects, the focus is not on targets per se but instead on induced cellular phenotypes. In this paper, we develop a set of criteria for evaluating and constructing small molecule libraries based on binding selectivity, target coverage and cell-based phenotypes as well as chemical structure and stage of clinical development. We find that data on structure, target spectrum and induced phenotypes are non-redundant, demonstrating that compounds should only be labeled as being functionally 'similar'
or 'different' when evaluated on diverse types of data.
We have codified our approach to scoring and assembling compound collections in three webbased applications: SelectivitySelectR, SimilaritySelectR and LibraryR, all of which draw data from ChEMBL and other user-specified sources. For a given list of targets, libraries are constructed so that each target is ideally bound by two high-affinity compounds with diverse target spectra and induced cellular phenotypes. Such data are incomplete but it is possible to increase the likelihood that a library will be functionally diverse by including compounds with non-similar structures -defined in this study as a Tanimoto similarity of Morgan2 fingerprints ≤ 0.2. This finding is in agreement with the general consensus 18,42 although our similarity cutoff is more stringent than usual. Additional therapeutics, beyond two per target, are included in subsequent tiers of the library because such compounds have intrinsic value for translational studies and drug repurposing. The bottom tiers in a library attempt to cover additional targets at lower levels of selectivity and also include historical compounds needed for comparison to previous libraries.
When six widely available kinase inhibitor libraries were evaluated, we found that the LINCS and SK libraries had the greatest diversity, broadest coverage of the kinome and the largest number of approved and investigational drugs. These were also the largest libraries analyzed, which increases the cost of creating and using them, particularly when complex dose-response or phenotypic assays are involved. The Dundee, EMD and SP libraries were substantially smaller (19% -54% the size of LINCS), but underperformed in one or more metrics. The PKIS library scored poorly with respect to structural and phenotypic diversity and number of approved drugs, but did have the largest number of compounds not included in any other collection. When we used LibraryR to design a new LSPOptimalKinase library we found that a collection of 256-compounds (Tiers A plus B; see Figure 6 ) outperformed all existing kinase libraries with respect to selectivity, target coverage, structural diversity and number of approved and investigational drugs. This library is also smaller than all but the existing SP library, which has substantially poorer coverage of the kinome.
Because our approach is data-driven and considers only public information, we have observed some differences between our top picks and first choice compounds suggested by others [18] [19] [20] . For example, www.chemicalprobes.org lists BI-D1870 as a selective inhibitor of the RPS6KA1 kinase, while we score this drug-target pair as being of unknown selectivity. In the published literature D1870 has only been tested against three targets, which LibraryR considers insufficient evidence of selectivity.
However, LibraryR has an option to add compounds from expert-opinion lists and then rank them relative all other compounds in a collection.
We also generated a list for a 3202-compound "mechanism of action library (LSP-MoA) that optimally covers the liganded genome and should be of general utility in semi-focused screening campaigns. We found that kinases were the target class best covered by this library, GPCRs were a distant second and many other multi-protein families had few if any selective inhibitors. This emphasizes the relative sparsity of selective coverage of targets considered 'ligandable,' at least by compounds whose structures are in the public domain. However, our approach to analyzing and designing compound libraries is data-driven so that the MOA library can be steadily improved as new data become available.
We expect the methods described here to assist in a variety of informatic, chemical biology and drug repurposing studies. For cell-based experiments, our tools can help to identify multiple, selective, and structurally diverse compounds against one or more target(s) of interest, thereby reducing the likelihood that off-target effects go unrecognized. Machine learning applications should also be able to make use of target affinity spectrum to investigate molecular profiling data on drug-treated cells, 
Calculating phenotypic fingerprint (PFP) correlation
Results from qualifying phenotypic screens were normalized to robust z-scores (r-scores). For each compound pair, Pearson's correlation was calculated on the subset of assays in which both compounds had been measured and least one of the compounds was active (i.e. r-score ≥3 or r-score ≤-3); correlation for pairs that had less than five of such assays were excluded. See script "03_calulating_PFPsimilarity.r".
Calculating L1000 correlation
Level 5 of the L1000 data was downloaded from GEO accession number GSE92742 on May 1 Figure 2C is the median distance for each pair of drugs.
Calculating selectivity score for compound-target interactions
The selectivity score for compound-target interactions was calculated according to an adapted version Selectivity classes, based on differential IC50, Pvalue and Data bias, were determined as outlined in Figure 3B . See script "05_calulating_selectivity.r".
Calculating Target Affinity Spectrum (TAS) similarity
The assignment of weights in the TAS vector was customized to each assay-type. In general, a weight of Five different data sources were used to compose the TAS: (i) dose-response data from Chembl v22_1 (see above), (ii) dose-response data from DiscoverX kinomescan, (iii) profiling data from DiscoverX at doses 0.1uM; 1uM; 10 uM, (iv) profiling data from Dundee (http://www.kinasescreen.mrc.ac.uk/kinase-inhibitors) at doses 0.01uM; 0.1uM; 1uM; 10uM, (v) curated nominal target annotations. Targets were normalized to gene_ids using gene symbol matches and manual conversions. Binding enrichments for datasources iii and iv were calculated per concentration per source see Figure S2 , Figure S2 , and Table S4 for conversion results. Nominal targets were extracted from manual searches in pubmed and by mining vendor information. Binding assertions were assigned as illustrated in figure 4A . TAS vectors of compound pairs were joined and entries where one of the compounds had an assertion ≤3 were kept. If the joined vector had a length ≥5, a weighted Jaccard similarity coefficient was calculated with the formula: Table S8 for full TAS vectors.
Assembling LSP-OptimalKinase and LSP-MoA libraries
LSP-OptimalKinase was developed to target human kinases (Table S7) , LSP-MoA was developed to target the liganded genome (Table S9 ). In the selectivity arm, the compound with the highest selectivity score was selected for each target. Then, a second compound within that same selectivity class (MS, SS, PS, UN) and a structural similarity ≤0.2 was selected. For targets with no second compound in MS class with sufficient structural dissimilarity, the SS class compounds were sourced to supply the second compound. The clinical development arm was assembled by selecting all molecules with max_phase 1-4 in MOLECULE_DICTIONARY table that had an affinity <1000 nM for one targets aimed at. Tiers were developed as illustrated in figure 5b . The members of molecular target classes for which the LSP-MoA library was analyzed were obtained from http://www.guidetopharmacology.org/download.jsp (accessed Dec 15th, 2017).
The Small Molecule Suite graphical user interface
The small molecule suite comprises the applications SelectivitySelectR, SimilaritySelectR and LibraryR.
For SelectivitySelectR, the selectivity score and mean affinity were calculated for all small molecules in the LINCS compound collection for each target their affinity was measured. In the application, users can select a target of interest and see the mean affinity and selectivity for all LINCS compounds with a known affinity for this target. All results can be downloaded for further used. For SimilaritySelectR, the structural similarity, TAS similarity and PFP similarity was calculated for all compound pairs in LINCS. In the application, users can select a reference molecule of interest to identify molecules that are similar or dissimilar in structure, target spectrum or induced phenotype. The application allows users to download information on the reference compound plus three additional compounds. For LibraryR, compounds were selected based on selectivity, clinical development stage and expert opinion status.
To enable selection for compounds on selectivity the selectivity score was calculated for all compounds-target pairs in ChEMBL V22_1 for which the target was a member of the liganded genome Figure legends Glaxo; and LINCS, the HMS-LINCS small molecule collection (see Table S1 for references and Web links). Number of Genes K in a s e s F u ll K in a s e s D a r k G P C R F u ll G P C R D a r k I o n C h a n n e l F u ll I o n C h a n n e l D a r k N H R F u ll T r a n s p o r t e r F u ll 
